Michael Davidson, NewAmsterdam CEO
July 29, 2024 08:00 AM EDTUpdated 11:15 AM
Deals
R&D
Pharma

NewAms­ter­dam suc­ceeds in the first of three key piv­otal stud­ies, pro­vid­ing hope to a trou­bled car­dio class

Max Bayer

Pharma Reporter

NewAms­ter­dam Phar­ma aced the first in a cas­cade of Phase 3 read­outs, show­ing that its lead car­dio med­i­cine took down lev­els of bad cho­les­terol. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 11 win­ners: Big bets on AI, new fron­tiers in edit­ing, a neu­ro re­nais­sance and Chi­nese chem­istry

Ex­clu­sive: J&J folds car­dio­vas­cu­lar and meta­bol­ic drug unit

No­vo Nordisk to de­crease some in­sulin pen man­u­fac­tur­ing, tran­si­tion sup­ply

No­vo Nordisk CEO skep­ti­cal of PBM promis­es in Sen­ate hear­ing on weight loss drug prices

Cas­sa­va and its for­mer ex­ecs set­tle SEC charges for ‘mis­lead­ing’ Alzheimer’s drug da­ta

sponsored

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

A service from the Financial Times